Skip to main content

Illumina Inc(ILMN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome

PR Newswire - Wed Jun 22, 2022

New assay brings validated HRD technology from Myriad Genetics to the Illumina TruSight™ Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer development and progression

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe